Azacitidine (5-Azacytidine)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza, CC-486

58 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza, CC-486) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Selleck's Azacitidine (5-Azacytidine) has been cited by 58 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza, CC-486) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vWXlAvOS13MDFOwG0> MnrNNVIuPzJiaB?= MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXfzSGpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|MzPDZpPkK2NVM{OjR4PD;hQi=>
Jurkat  MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSwMlEuPTBizszN NEDYWncyOi15MjDo Mof0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4LBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUOzNlQ3Lz5{NkGzN|I1PjxxYU6=
CA46 MmGxSpVv[3Srb36gRZN{[Xl? NUTZWnExOjEEoNM1US=> NY\MXpFYPDhiaB?= MmfYbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w MnjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{OyOFYoRjJ4MUOzNlQ3RC:jPh?=
Raji  NH;LOYZHfW6ldHnvckBCe3OjeR?= MUixOeKhyrWP MXe0PEBp MYfpcoNz\WG|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25? MoDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{OyOFYoRjJ4MUOzNlQ3RC:jPh?=
Jurkat  NIX3OpdHfW6ldHnvckBCe3OjeR?= NEe5PJg{NjYEoNM1US=> NFHuVJg1QCCq Mnq4bY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w M{izNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUOzNlQ3Lz5{NkGzN|I1PjxxYU6=
MDA-MB-231 MlvLSpVv[3Srb36gRZN{[Xl? NFjMPVQyNzJwNT:1JO69VQ>? NIizemU1QCCq MXXk[YNz\WG|ZYOgeIhmKFCWUF6xNkBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kA2yqEQvF2gOFjDqGh? Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUeyNlkoRjJ3OEG3NlI6RC:jPh?=
MDA-MB-231 M1jmcmZ2dmO2aX;uJGF{e2G7 M1L2cFEwOi53L{Wg{txO NIjleI01QCCq MX7pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCHLXPh[IhmemmwIH3SUmEh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFIvPcLizszN[o9zKDR6wrDo NHHlOGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixO|IzQSd-MkW4NVczOjl:L3G+
MDA-MB-231 MoXBSpVv[3Srb36gRZN{[Xl? MVGxM|IvPS93IN88US=> NGW3XJIzPC92ODDo MnrEbY5lfWOnczCgd4lodmmoaXPhcpQhWEGUUDDjcIVifmGpZTDh[pRmeiB2ODDo NWTpZXNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVczOjlpPkK1PFE4OjJ7PD;hQi=>
MCF-7 MVXGeY5kfGmxbjDBd5NigQ>? M{jsNFEwOi53L{Wg{txO MVeyOE81QCCq MY\pcoNz\WG|ZYOgVGFTWCClbHXheoFo\cLi M3m5O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEG3NlI6Lz5{NUixO|IzQTxxYU6=
MDA-MB-231  MmTYSpVv[3Srb36gRZN{[Xl? MYOxM|IvPS93IN88US=> NXWzb49HOjRxNEigbC=> MkTmbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJI1qWk6DLUGyOEBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gOUDPxE1? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzN{KyPUc,OjV6MUeyNlk9N2F-
A498 Ml:ySpVv[3Srb36gRZN{[Xl? MnzMNVAhyrWP MYG3NkBp NHTOOoVqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> M2D4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[5NFg3Lz5{NUW2PVA5PjxxYU6=
CaKI-2 MV7GeY5kfGmxbjDBd5NigQ>? NFWwZmIyOCEEtV2= MlTkO|IhcA>? M2LMNYlv\HWlZYOgeIhmKEGGQV3UV|E5KGenbnWg[ZhxemW|c3nvci=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4OUC4Okc,OjV3NkmwPFY9N2F-
Ketr-3 NWTmTnlITnWwY4Tpc44hSXO|YYm= NIDaVJAyOCEEtV2= MnTlO|IhcA>? M{LJO4lv\HWlZYOgeIhmKEGGQV3UV|E5KGenbnWg[ZhxemW|c3nvci=> M4S2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[5NFg3Lz5{NUW2PVA5PjxxYU6=
A253 NF\MeoxHfW6ldHnvckBCe3OjeR?= MYexNEDDvU1? MVSwMVQh\A>? NGTRR|ZqdmO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCuZY\lcEBw\iC2aHWgUVNTyqCjZoTldkAzPCCq MonXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEW1N|YoRjJ3NEi1OVM3RC:jPh?=
A253 NFj2eGlHfW6ldHnvckBCe3OjeR?= NXvEeHd6OTBiwsXN MkX1O|IhcA>? MV7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{ MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6NUWzOkc,OjV2OEW1N|Y9N2F-
A253 MYTGeY5kfGmxbjDBd5NigQ>? MlWxNVAhyrWP NGC4UGQxNTRiZB?= NIq5[2lz\WS3Y3XzJJRp\SB3LX3leIh6dGO7dH;zbY5mKGOxboTlcpQ> MnfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEW1N|YoRjJ3NEi1OVM3RC:jPh?=
PC3 NY\2ZYpwTnWwY4Tpc44hSXO|YYm= M4mye|AvOiEQvF5CpC=> NFHpSGc1KGR? MXvpcoNz\WG|ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4 NF3mfW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O|M1OCd-MkW0O|c{PDB:L3G+
MCF7 MkHWSpVv[3Srb36gRZN{[Xl? M4TVNFAvOyEQvF5CpC=> MVy0JIQ> MUnpcoNz\WG|ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4 NUf1dVY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{PDBpPkK1OFc4OzRyPD;hQi=>
PC3 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqwMlIh|ryPwrC= NEDsZ3A1KGR? MYLk[YNz\WG|ZYOgeIhmKGOnbHyg[5Jwf3SqIITvJFIxNjNnIHPvcYJqdmWmIIfpeIghT1ONMUK2 M3[xb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N|QxLz5{NUS3O|M1ODxxYU6=
MCF7 MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPod41yOC5|IN88UeKh M3;YZlQh\A>? NVKwXmtE\GWlcnXhd4V{KHSqZTDj[YxtKGe{b4f0bEAzPC56JTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> NGHOOXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O|M1OCd-MkW0O|c{PDB:L3G+
BGC-823 M1LaTmZ2dmO2aX;uJGF{e2G7 NEe1WpE2yqEQvF2= NUG3U5NJPzJiaB?= NXvwdpJL\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5NUezN{c,OjV2N{W3N|M9N2F-
MKN28 MXLGeY5kfGmxbjDBd5NigQ>? M{PFW|XDqM7:TR?= MUG3NkBp M33SR4Rm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk> MoPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N|MoRjJ3NEe1O|M{RC:jPh?=
SGC-7901 MV;GeY5kfGmxbjDBd5NigQ>? M2fvPFXDqM7:TR?= Mkn2O|IhcA>? NID5bZBl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 NW\xO2VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|U4OzNpPkK1OFc2PzN|PD;hQi=>
MKN45 MYLGeY5kfGmxbjDBd5NigQ>? MlrXOeKh|ryP Mn\vO|IhcA>? NW\CZYlT\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? MnrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N|MoRjJ3NEe1O|M{RC:jPh?=
BGC-823 NILMRVZHfW6ldHnvckBCe3OjeR?= M3LQ[|XDqM7:TR?= MU[3NkBp MmLN[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= M2HFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe1O|M{Lz5{NUS3OVc{OzxxYU6=
MKN28 NVTPd4pCTnWwY4Tpc44hSXO|YYm= MX[1xsDPxE1? NEnNdW04OiCq Ml25[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= MonpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{W3N|MoRjJ3NEe1O|M{RC:jPh?=
SGC-7901 NYLrfVJpTnWwY4Tpc44hSXO|YYm= M1nqW|XDqM7:TR?= MVu3NkBp MlTi[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= NFn2O5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3OVc{Oyd-MkW0O|U4OzN:L3G+
MKN45 MmTBSpVv[3Srb36gRZN{[Xl? MVy1xsDPxE1? M2rtcFczKGh? M2rqVIRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIGDSUE0{KHOrZ37p[olk[W62bIm= NYjacFlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|U4OzNpPkK1OFc2PzN|PD;hQi=>
HREC NI\SXGlHfW6ldHnvckBCe3OjeR?= MnTPOU8yOMLizszN MVW0PEBp M2r2eYlv\HWlZYOgVGVFTiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV|NUK3OFc9N2F-
HRPE MX3GeY5kfGmxbjDBd5NigQ>? NGjISm02NzFywrFOwG0> NXfVcnp7PDhiaB?= NIHP[mFqdmS3Y3XzJHBGTEZiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV|NUK3OFc9N2F-
HREC NWL1boxoTnWwY4Tpc44hSXO|YYm= NF7QSXE2NzFywrFOwG0> M3fzeFQ5KGh? MYrkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLQ1HNMVEhMG6xdDDwdo91\WmwIHzleoVtKGmwIFjSVGUh[2WubIOpMEBKVC1zzsKg[I9{\S2mZYDlcoRmdnSueR?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV|NUK3OFc9N2F-
HRPE NIfVcZlHfW6ldHnvckBCe3OjeR?= M2XINFUwOTEEoN88US=> M{T3XFQ5KGh? NXnGXGVb\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWwuOc7{LDDhcoQhVU2SMjDkc5NmNWSncHXu[IVvfGy7 MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN3Mke0O{c,OjV|NUK3OFc9N2F-
MSCs MYrGeY5kfGmxbjDBd5NigQ>? MYWxNEDPxE1? M4rnNlI1KGh? MmTndJJwdW:2ZYOgeIhmKGOxbX3peI1mdnRib3[gUXNEeyC2bzDtfY9k[XKmaXHsJIRq\m[ncnXueIlifGmxbh?= NXPMfZBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOVE{QTVpPkK1N|UyOzl3PD;hQi=>
HL-60 MlzaSpVv[3Srb36gRZN{[Xl? MUC1JO69VQ>? MlzwO|IhcA>? MlfLSG1UVw>? NVLjbXl4e2mpbnnmbYNidnSueTD1dJJm\3WuYYTld{BbVkZ|OEKg[ZhxemW|c3nvci=> MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MUmwOFkoRjJ3M{G5NFQ6RC:jPh?=
MV4-11 M4PqbWZ2dmO2aX;uJGF{e2G7 NILFTpk2KM7:TR?= NH62[pI4OiCq NYjmWGZjTE2VTx?= MnK4d4lodmmoaXPhcpRtgSC3cILl[5Vt[XSnczDaUmY{QDJiZYjwdoV{e2mxbh?= M4rQR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{G5NFQ6Lz5{NUOxPVA1QTxxYU6=
A2780 NX3hNW1zTnWwY4Tpc44hSXO|YYm= MnTyOUDDvU4EoB?= MmHpO{Bl NV7kWZpscW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?= MlnmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
CP70 M{LrbWZ2dmO2aX;uJGF{e2G7 M2\iOVUhyrWPwrC= NIDCbpk4KGR? NFHvOo1qdmO{ZXHz[ZMhTE6DIH3leIh6dGG2aX;uJIxmfmWu MljwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
A2780 M3r3SWZ2dmO2aX;uJGF{e2G7 NX3K[IZMPSEEtV5CpC=> NUK1[YNVPyCm NVf6epdnf2Wja3Xud{B1cGVibHX2[Ywhd2ZibXX0bJlt[XSrb36= NUPwT3czRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVk3QTRpPkK1Nlk6Pjl2PD;hQi=>
CP70 Moq1SpVv[3Srb36gRZN{[Xl? MWq1JOK2VcLi MXW3JIQ> MnfNe4Vic2WwczD0bIUhdGW4ZXygc4YhdWW2aInsZZRqd25? MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUm2PVQoRjJ3Mkm5Olk1RC:jPh?=
OCM3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6wMlUwOS9{IN88US=> M3fBZ|ch\A>? MUPEUXNQ NXrHZ4VucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{fwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
92.1 M2jYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrkcZkxNjVxMT:yJO69VQ>? MVu3JIQ> MYfEUXNQ M1jJVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MorFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM1 M3XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jKblAvPS9zL{Kg{txO MnG2O{Bl MYrEUXNQ NUjPOIZGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
OMM1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjTe2gxNjVxMT:yJO69VQ>? Mm[5O{Bl MoLISG1UVw>? M3u4OIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M1u4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
Mel 285 M4ficGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP6ZYwxNjVxMT:yJO69VQ>? NG\CNIQ4KGR? NVHhe21mTE2VTx?= MkCybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
Mel 290 NY\scoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjSNE42NzFxMjFOwG0> NIH4blQ4KGR? MVHEUXNQ Mlr4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{LNPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM3 MUHGeY5kfGmxbjDBd5NigQ>? NGLxUYsxNjVxMTFOwG0> NX;DbJp1PDhiaB?= Mlf2SG1UVw>? MX;k[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 NEHtbJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
92.1 M37G[mZ2dmO2aX;uJGF{e2G7 NVO2bo9EOC53L{Gg{txO NYDSTow6PDhiaB?= M2Lmb2ROW09? M2LPcoRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM1 NIL2RpZHfW6ldHnvckBCe3OjeR?= NWSzSWZXOC53L{Gg{txO MkTxOFghcA>? M{fQd2ROW09? NVnlNYpL\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
OMM1 MXHGeY5kfGmxbjDBd5NigQ>? Mo[2NE42NzFizszN MlPSOFghcA>? MXvEUXNQ M4KweIRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? M1LWbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
Mel 285 M{\qVGZ2dmO2aX;uJGF{e2G7 NF[zeJQxNjVxMTFOwG0> MofpOFghcA>? NUjBdXc{TE2VTx?= MkfU[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NH7Re5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
Mel 290 NVSyUoJTTnWwY4Tpc44hSXO|YYm= MorFNE42NzFizszN NHHPfnY1QCCq NYLPd29vTE2VTx?= M3HYO4Rm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? NYnPZXJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
OCM3 NUjRW4h6TnWwY4Tpc44hSXO|YYm= Mm\2NE42NzFizszN MVG0PEBp M37UNWROW09? M1PLfYRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA> NWLJ[Xl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
Mel 290 NEDSOJFHfW6ldHnvckBCe3OjeR?= M2DKZVAvPS9zIN88US=> MV:0PEBp M4DE[2ROW09? NHnacXRl\WO{ZXHz[ZMhcW64YYPpc44h\G:|ZTDk[ZBmdmSnboTsfeKh NIK1XGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0Olk5OSd-MkWxOFY6QDF:L3G+
OMM1 M2W1PWZ2dmO2aX;uJGF{e2G7 NEPFW4gxNjVxMTFOwG0> MX[0PEBp NUfD[5NQTE2VTx?= MVjk[YNz\WG|ZYOgbY53[XOrb36g[I9{\SCmZYDlcoRmdnSuedMg M1OxWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
OCM1 NXK5T2E1S2WubDDWbYFjcWyrdImgRZN{[Xl? MmXaNE42NzFizszN MV21JIQ> MV7EUXNQ NYTnUIkx\GWlcnXhd4V{KHKjZHnheIlwdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIlvcGmkaYTpc44> NW[3OY5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFY6QDFpPkK1NVQ3QThzPD;hQi=>
92.1 NY\m[2FrS2WubDDWbYFjcWyrdImgRZN{[Xl? MnjyNE42NzFizszN M3\NcVUh\A>? NF7CZnZFVVOR NGDVc5pl\WO{ZXHz[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgbY5pcWKrdHnvci=> MlPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM1 Mk\LSpVv[3Srb36gRZN{[Xl? MXiwMlUwOSEQvF2= M3f1d|Q5KGh? M{LnVGROW09? NV75R2Y6[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=> MlT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNE[5PFEoRjJ3MUS2PVgyRC:jPh?=
OCM3 M1HjcWZ2dmO2aX;uJGF{e2G7 NW\xXnRtOC53L{Gg{txO NILze3M1QCCq NVPLZ|NoTE2VTx?= NF;YNGlk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp M4LTR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUS2PVgyLz5{NUG0Olk5OTxxYU6=
92.1 MUXGeY5kfGmxbjDBd5NigQ>? Mnn4NE42NzFizszN NEnubmQ1QCCq NGradXNFVVOR NXHz[2xs[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2Nkm4NUc,OjVzNE[5PFE9N2F-
IMR32 MlL6SpVv[3Srb36gRZN{[Xl? MWGzJO69VQ>? M3rqTFczKGh? Ml;ZSG1UVw>? NHnXOoFqdmS3Y3XzxsBxOTlvSV7LOITDqGW6cILld5Nqd28EoIPp[45q\mmlYX70cJk> NYSyW5UzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFQ5PTBpPkK1NVA1QDVyPD;hQi=>
IMR5-75 NHuy[XRHfW6ldHnvckBCe3OjeR?= MmmxN{DPxE1? M12zUlczKGh? M{DUNmROW09? NGrZTZhqdmS3Y3XzxsBxOTlvSV7LOITDqGW6cILld5Nqd28EoIPp[45q\mmlYX70cJk> NWnROpl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFQ5PTBpPkK1NVA1QDVyPD;hQi=>
Be(2)-C Mn\SSpVv[3Srb36gRZN{[Xl? MluyN{DPxE1? M1njb|czKGh? NVzvW4VtTE2VTx?= M3qzOIlv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNEi1NEc,OjVzMES4OVA9N2F-
Bxpc-3 NVXsb5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW5OU8yOCEQvF2= MYiyOE81QC95MjDo NGTKVpJqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCEeIDjMVMh[2WubIOgbY4hfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6ncoO= MkDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N|EoRjJ3ME[xO|MyRC:jPh?=
Bxpc-3 NF3X[|VCeG:ydH;zbZMhSXO|YYm= NGfKboU2NzFyIN88US=> NW\SSFF2OjRxNEivO|IhcA>? NETmRXVqdmS3Y3XzJIFxd3C2b4Ppd{BqdiC2aX3lMUBidmRiY3;uZ4VzdnS{YYTpc44hdWGwbnXydy=> NGD0Xog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVc{OSd-MkWwOlE4OzF:L3G+
Bxpc-3 MofjSpVv[3Srb36gRZN{[Xl? NF[4SXM2NzFyIN88US=> M2rMdlI1NzR6L{eyJIg> MVHk[YNz\WG|ZYOg{tIu[2G2ZX7pckBmgHC{ZYPzbY9vKGGodHXyJFI1KGh? Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N|EoRjJ3ME[xO|MyRC:jPh?=
Bxpc-3 NETEfXlHfW6ldHnvckBCe3OjeR?= MnT2OU8yOCEQvF2= MnznNlQwPDhxN{KgbC=> MX\k[YNz\WG|ZYOgZ5lkdGmwREGg[ZhxemW|c3nvckBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gNVAh|ryP MmGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkG3N|EoRjJ3ME[xO|MyRC:jPh?=
Bxpc-3 MXXGeY5kfGmxbjDBd5NigQ>? NGraXno2NzFyIN88US=> NH7kT48zPC92OD:3NkBp M1u2eIRwf25vcnXneYxifGWVIHOtcZlkKG2UTlGg[ZhxemW|c3nvckBqdiC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXydy=> NV7hb4tRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlE4OzFpPkK1NFYyPzNzPD;hQi=>
HL-60 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxMlAh|ryP NGXEOmE1QCCq MYfzbYdvcW[rY3HueIx6KGmwaHnibZR{KEiOLU[wJINmdGxiZ4Lve5RpyqB? MkTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUGxNVkoRjJ3MEWxNVE6RC:jPh?=
HL-60 NV\FflR6TnWwY4Tpc44hSXO|YYm= M2jhPFEvOCEQvF2= NX3IbYhoPDhiaB?= NEnBSIxqdmO{ZXHz[ZMheDJzV1HGNU9EUVBzwrDhcoQh[2G|cHHz[U0{KGW6cILld5Nqd28EoB?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MUGxPUc,OjVyNUGxNVk9N2F-
HL-60 M2TlO2Z2dmO2aX;uJGF{e2G7 NHHTSlMyNjBizszN NVvmfWFwPDhiaB?= NGDkeJll\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= MlXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUGxNVkoRjJ3MEWxNVE6RC:jPh?=
HuTu-80  M1TDT2Z2dmO2aX;uJGF{e2G7 NHPWbZcyNzVxMUCg{txO NUnlOplVPDhxN{KgbC=> MX\pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gbJVu[W5iTmDDNWwyKG2UTlGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MESwOlIoRjJ2OUC0NFYzRC:jPh?=
Caco2  MkDvSpVv[3Srb36gRZN{[Xl? NULYfZZiOTBizszN NESxWJc1QCCq M2HWRYlv[3KnYYPld{BPWENzTEGg[ZhxemW|c3nvci=> MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MESwOlIoRjJ2OUC0NFYzRC:jPh?=
HepG2  MorzSpVv[3Srb36gRZN{[Xl? NIP4SmQxNTJ3IN88US=> NFG2bpczPCCq NHSxNlNl\WO{ZXHz[ZMhe3WkdHnsbZNqdi:tZYjpckB1gXCnIEmgLHBEW0t7KTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6 NGHtV2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HepG2  MVLGeY5kfGmxbjDBd5NigQ>? NYXGeIJFOC1{NTFOwG0> MmDZNlQhcA>? NU\tclJscW6lcnXhd4V{KGyxdzDk[Y5{cXS7IHzpdI9xem:2ZXnuJJJm[2WydH;yJEhNTEyUKTDn[Y5mKGW6cILld5Nqd28EoB?= NHrZXJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HepG2  M3nmbGZ2dmO2aX;uJGF{e2G7 NXPpZpE6OTBizsztxsA> NF:1ZpgxNTJ2IHi= M37FdIRm[3KnYYPld:KhWEOVS{pCpIFv\MLiSF3HR3LDqGW6cILld5Nqd25iYX7kJIlv[3KnYYPld{BNTEyUIHX4dJJme3Orb36gZYZ1\XJiNjDo MlnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUW2OFYoRjJ2OEW1OlQ3RC:jPh?=
HepG2  MXHGeY5kfGmxbjDBd5NigQ>? MlToNVAh|ryv MUmyOEBp M2DMW5Bzd22xdHXzJIN6fG:|b3zpZ{Bv\XW2cnHsJIxqeGmmIHHjZ5VufWyjdHnvckBqdmSncHXu[IVvfGy7IH;mJIV5d2enbn;1d{BtcXCxcILveIVqdnN? M3nYblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW1OlQ3Lz5{NEi1OVY1PjxxYU6=
HepG2  NGrG[29HfW6ldHnvckBCe3OjeR?= MmfxNVAh|ryv NHzBTnMzPCCq MnnQdJJmfmWwdIOgV3JGSlBicILvZ4V{e2mwZx?= NIDle3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OVY1Pid-MkS4OVU3PDZ:L3G+
HC45  Ml7hSpVv[3Srb36gRZN{[Xl? M4\RcVXDvU4EoB?= MYS0JIQ> MkHBdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF? NEP0epU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2NlgxQSd-MkS3OlI5ODl:L3G+
CNDT2  Mmf4SpVv[3Srb36gRZN{[Xl? MWq1xtVOyqB? MX:0JIQ> Ml\pdoVlfWOnczD0bIUhdWW2aInsZZRqd25ibHX2[Yx{KG:oIGfJSlEtKFBzNjygR3hEVDF2LDDOT3gz6oDVMzygR2RJOSxiTFHNRVEtKGGwZDDDWG5PSjF? NWPs[GlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OlI5ODlpPkK0O|YzQDB7PD;hQi=>
CNDT2  M2TUSWZ2dmO2aX;uJGF{e2G7 NGTKR2s2yrWPwrC= MUS0JIQ> Mn3FbY5kemWjc3XzJIdmdmViZYjwdoV{e2mxbjDv[uKhX0mIMTygVFE3NCCFRFixMOKhVEGPQUGsxsBidmUEoFPUUm5DOQ>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MkiwPUc,OjR5NkK4NFk9N2F-
T-cells MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DDbVUwOjBizszN MVqwMVQ5KGh? NV;zR444cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWHEflF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O|U4Ojh|PD;hQi=>
CD3+ T-cells MV\GeY5kfGmxbjDBd5NigQ>? MVy1M|IxKM7:TR?= NHPOOm41QCCq NHLVWYt2eHKnZ4XsZZRmeyCyMUWg[ZhxemW|c3nvci=> NGLUd|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells MknlSpVv[3Srb36gRZN{[Xl? NIn6d|Q2NzJyIN88US=> MmjNOFghcA>? NGH1eWV2eHKnZ4XsZZRmeyCyMUWg[ZhxemW|c3nvci=> M4DFPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O|I5OzxxYU6=
CD8+ T-cells MmfrSpVv[3Srb36gRZN{[Xl? NUX1bms{PS9{MDFOwG0> M2jKRlQ5KGh? MWr1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= NF6xSFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O|I5Oyd-MkS3OVczQDN:L3G+
CD3+ T-cells M{jmVGZ2dmO2aX;uJGF{e2G7 NUnOT2ZGPS9{MDFOwG0> MlvEOFghcA>? NFHLNnZ2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCIT2jQNy=> NUHjXY02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O|U4Ojh|PD;hQi=>
CD4+ T-cells MV;GeY5kfGmxbjDBd5NigQ>? NVjPRpI6PS9{MDFOwG0> M4fuUVQ5KGh? NGnZXY12eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCIT2jQNy=> NH7tXG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe1O|I5Oyd-MkS3OVczQDN:L3G+
CD4+ T-cells NYnwRmpRTnWwY4Tpc44hSXO|YYm= Mn;4OU8zOCEQvF2= NFjnPHg1QCCq MnnUdoVlfWOnczDURmVVOcLibWLORUBmgHC{ZYPzbY9v NUjITYlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O|U4Ojh|PD;hQi=>
CD4+ T-cells Ml;0SpVv[3Srb36gRZN{[Xl? M4fUU|UwOjBizszN MlP2OFghcA>? MV31dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[uKhWk:UzsP0xsA> MnrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NUeyPFMoRjJ2N{W3Nlg{RC:jPh?=
CD4+ T-cells M{OwV2Z2dmO2aX;uJGF{e2G7 MUW1M|IxKM7:TR?= M3;4OlQ5KGh? MmnXbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? NVLPSGJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVczQDNpPkK0O|U4Ojh|PD;hQi=>
CD8+ T-cells NWLCbIdMTnWwY4Tpc44hSXO|YYm= NXLv[IdYPS9{MDFOwG0> NWTFPJBIPDhiaB?= NUHENWNucW6qaXLpeJMhdWWvb4L5JHQu[2WubIO= M3XkSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O|I5OzxxYU6=
CD3+ T-cells Mlr5SpVv[3Srb36gRZN{[Xl? NIXiTIo2KM7:TR?= NFLVU3g1QCCq MmK5doVlfWOnczDsc45oNXSncn2gcYVud3K7IHPlcIwheGinbn;0fZBm M3rX[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W3Nlg{Lz5{NEe1O|I5OzxxYU6=
U937 MXzBdI9xfG:|aYOgRZN{[Xl? MXqxNEDPxE1? NHTqW4c4OiCq MV\pcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6MEi2OUc,OjR4OEC4OlU9N2F-
HL-60 M{O0NmFxd3C2b4Ppd{BCe3OjeR?= NYjNWXJIOTBizszN MkLzO|IhcA>? NHSxcFdqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M4HId|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiwPFY2Lz5{NE[4NFg3PTxxYU6=
MCF7 NGfpcVdHfW6ldHnvckBCe3OjeR?= NYPyNY5YPSEQvF2= NWT4dnRSPDhiaNMg NY\Wd45w\Gm|cHzhfZMhe2WuZXP0bZZmKHSxeHnjbZR6KHSxd3Hy[EB{fXOyZX7k[YQhVUOILUegZ4VtdHN? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ|M{O1NEc,OjR4M{OzOVA9N2F-
MCF7 MnHySpVv[3Srb36gRZN{[Xl? M{HFN|ExKM7:TR?= NVrnZXU5OjRiaNMg NUTIRpdpcW6mdXPld{B1cGViY3zlZZZi\2Vib3[gZ4F{eGG|ZTC3JIFv\CCSQWLQxsA> Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN|UxRC:jPh?=
MCF7 NI\HdZJHfW6ldHnvckBCe3OjeR?= MVyw5qCUOC53IN88UeKh MV:3JIQ> M3vPS4lvcGmkaYTzJJRp\SCpcn;3eIghVUOILUegeJVud3K|cHjldoV{KGmwIIP1d5BmdnOrb36gZ5VtfHW{ZYRCpC=> NF;UbJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN|M2OCd-MkS2N|M{PTB:L3G+
MCF7 NWK0WJBjTnWwY4Tpc44hSXO|YYm= Ml:0NE42KM7:TdMg MmfzNVQh\A>? M4rzZ5Jm\HWlZYOgeIhmKHOrenWgc4YhVUOILUegZ49td26rZYOg[Y1j\WSmZXSgbY4he2:odDDh[4Fz NF\uXlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN|M2OCd-MkS2N|M{PTB:L3G+
MCF7 MXzGeY5kfGmxbjDBd5NigQ>? Ml[yNE4xPeLCk{KwJO69VQ>? NX:0cnhzOSCm NYnL[VJEemWmdXPld{B1cGViY3zvcoFtKHO3co\peoFtKG:oIF3DSk04KGOnbHzzJIlvKG2xbn;sZZlmeiCldXz0eZJmew>? NVrkPXJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N|M{PTBpPkK0OlM{OzVyPD;hQi=>
T47D  Mo\QSpVv[3Srb36gRZN{[Xl? NXzPSIJMOC53IN88US=> M1zrTVQh\A>? NYDXWmYxcW6qaXLpeJMhfHWvb4LzdIhmemViZn;ycYF1cW:w NWfxcnViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N|M{PTBpPkK0OlM{OzVyPD;hQi=>
MCF7 MnHBSpVv[3Srb36gRZN{[Xl? M3XwPVAvPeLCk{GwJO69VQ>? M4fPZlQ5KGkEoB?= MXXpcohq[mm2czD0bIUh\2GyIHPsc5N2emViaX6geIhmKHexdX7kJIhm[WyrbnegZZN{[Xl? NFm0dJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zN|M2OCd-MkS2N|M{PTB:L3G+
MCF7 NWn0e|N1TnWwY4Tpc44hSXO|YYm= Mnz1NE8yOCEQvF2= MnHPNlQhcA>? MljPbY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVFk> M3PFdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOzN|UxLz5{NE[zN|M2ODxxYU6=
MDA-MB-231  MnLESpVv[3Srb36gRZN{[Xl? NIniOGoxNjYkgKOxNEDPxE1? MVyzOkBp NGnMU4xqdmirYnn0d{B1cGVibXnndoF1cW:w MlvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{OzOVAoRjJ2NkOzN|UxRC:jPh?=
SKM1-S NGnDPIxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXS0PEBpenN? NX\jUXpjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT20yNVNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHhVXCCjc4PhfUwhUUN3MDC9JFAvPSEQvF2u M1n4[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEm0PVM5Lz5{OEC5OFk{QDxxYU6=
SKM1-S MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MXq0PEBpenN? NVPVRlFmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT20yNVNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JGRCWElvc4ThbY5qdmdvYnHz[YQh\myxdzDjfZRwdWW2cnnjJI1mfGixZDygSWM2OCB;IECuOVEh|ryPLh?= MlK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyOUS5N|goRjJ6MEm0PVM5RC:jPh?=
A427 NEX5em1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXq5OkBpenN? NFr6b25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0Nlch[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IHPyfZN1[WxidnnvcIV1KGG|c3H5MEBKSzVyIE2gNE43OyEQvF2u MmrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2M{SxOlMoRjF6NEO0NVY{RC:jPh?=
KYSE70 MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MnzmPVYhcHK| NUDjWZdxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLXXNGPzBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JINzgXO2YXygeolwdGW2IHHzd4F6NCCLQ{WwJF0hOS53OTFOwG0v MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR|NEG2N{c,OTh2M{SxOlM9N2F-
5637 MoSzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NETuW|c6PiCqcoO= NXHN[npuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjC1OlM4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDjdpl{fGGuII\pc4xmfCCjc4PhfUwhUUN3MDC9JFEvPzNizszNMi=> M1jURVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEO0NVY{Lz5zOESzOFE3OzxxYU6=
HT-29 MlfoRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Ml\ZPVYhcHK| NEm1SphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCzMlgh|ryPLh?= NHjRSYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e4OFQ6Lz5{N{e4OFQ6RC:jPh?=
P388 M4rLZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NW\6Z4NOPDhiaILz NGrSfI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIGCzPFgh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWg{txONg>? NFzYUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e4OFQ6Lz5{N{e4OFQ6RC:jPh?=
MCF7 NUfBS5U5SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MYK5OkBpenN? M3K2Z2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB7NjDodpMh[nliY4L5d5RidCC4aX;s[ZQh[XO|YYmsJGlEPTBiPTC2Mlc5KM7:TT6= NILyb2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESzOFE3Oyd-MUi0N|QyPjN:L3G+
U373-MAGI NIi0[JNCdnSrdnnyZYwh[XO|YYm= NFS3WoszPSC2bzC0NFAhfU1? M{DReVIhfG9iN{KgbJJ{ MkDzRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDnZYchdGW4ZXygZZQhOjVidH:gOFAxKHWPIHHmeIVzKDJidH:gO|IhcHK|IHL5JJFRS1JibXX0bI9l MoCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI MoPDRY51cX[rcnHsJIF{e2G7 MYSyOUB1dyB2MECgeW0> MXyyJJRwKDd{IHjydy=> NWjnbG8xSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBWPS2pYXegcIV3\WxiYYSgNlUhfG9iNECwJJVOKGGodHXyJFIhfG9iN{KgbJJ{KGK7IIHQR3IhdWW2aH;k NF60bY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+
L1210 MXHDfZRwfG:6aXPpeJkh[XO|YYm= MkOzR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFEzOTBiY3XscJMh[XO|ZYPz[YQh[XNiY3Xzd4F1cW:wIH;mJIdzd3e2aB?= NGrOR4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi94OUCyOkc,PjlyMk[8M4E,
TC32 M2DEdZFJXFNiYYPzZZk> NFe2fZJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= NUPnSWw6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 Mlr4dWhVWyCjc4PhfS=> M1LUe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NH\XOWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NUXBV254eUiWUzDhd5NigQ>? MnPadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| MnX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MnXtdWhVWyCjc4PhfS=> M17Rc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NGjq[4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 Mlm3dWhVWyCjc4PhfS=> NGHQVWpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= M3XmelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MXrxTHRUKGG|c3H5 M4LMd5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= NH;jWHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NVW5dZlKeUiWUzDhd5NigQ>? NFW4fWNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NW\NWmFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC M3u0NJFJXFNiYYPzZZk> M1X3UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NX7tVm1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SKM1-S NVnldFU{SXCxcITvd4l{KGG|c3H5 NH\SWlkyKHWP MnPYTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS12xMXMh[2WubIOgZZN{\XO|ZXSgZZMh[2G|cHHz[UA{KGOuZXH2ZYdmKGG2IEGgeW0h[nliV3XzeIVzdiCkbH;0JI1mfGixZB?= M1XaUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEm0PVM5Lz5{OEC5OFk{QDxxYU6=
MCF7 M4fldmZ2dmO2aX;uJIF{e2G7 MX2xOUB2VQ>? MXq3NkBpenN? MULJcohq[mm2aX;uJI9nKFWKUl[xJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gcYV1cHmuYYTpc44h[XRiUlHSJIJmfGFiZYjvckBifCBzNTD1UUBi\nSncjC3NkBpenNiYomgcYV1cHmuYYTpc44he3CnY3nmbYMuWEOUIH3leIhw\A>? NH22UXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C0PVU4Pyd-MkewOFk2Pzd:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 ; 

PubMed: 28210112     


AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control.

c-PARP / p-H2AX / H2AX; 

PubMed: 28210112     


AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘

28210112
Immunofluorescence
HMGB1 ; 

PubMed: 29097772     


U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemセ᎒

29097772
Growth inhibition assay
Cell viability ; 

PubMed: 28210112     


AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖

28210112
In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
- Collapse
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
in solvent
Synonyms 5-AzaC,Ladakamycin, AZA,5-Aza, CC-486
Smiles C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04891068 Recruiting Drug: Azacitidine Breast Cancer Female|Breast Cancer Invasive University of Illinois at Chicago October 2021 Phase 2
NCT04722601 Not yet recruiting Drug: Venetoclax|Drug: Obinutuzumab|Drug: CC-486 Follicular Lymphoma University of Chicago September 2021 Phase 1|Phase 2
NCT05001828 Not yet recruiting Drug: ADI-PEG 20 Acute Myeloid Leukemia Adult Polaris Group August 2021 Phase 1
NCT04912063 Suspended Drug: Lemzoparlimab|Drug: Azacitidine|Drug: Venetoclax Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS) AbbVie June 25 2021 Phase 1
NCT04737343 Not yet recruiting Drug: Leflunomide|Drug: Azathioprine Tablets ANCA Associated Vasculitis|Maintenance Therapy Chinese SLE Treatment And Research Group|Shanghai Zhongshan Hospital|Affiliated Hospital of Jilin University ChangchunChina|Second Affiliated Hospital of Nanchang University|The First Affiliated Hospital of Anhui Medical University|Beijing Shijitan Hospital Capital Medical University|The Affiliated Hospital of Inner Mongolia Medical University|The First Affiliated Hospital of Kunming Medical College|Sichuan Province People''s Hospital|Second Affiliated Hospital School of Medicine Zhejiang University May 1 2021 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) supplier | purchase Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) cost | Azacitidine (5-Azacytidine) manufacturer | order Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID